9-Fluor-11β,17,21-trihydroxy-16α-methylpregna-1,4-dien-3,20-dion-17-valerat

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H361：Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen.

  H362：Kann Säuglinge über die Muttermilch schädigen.

  H373：Kann die Organe schädigen bei längerer oder wiederholter Exposition.

• Sicherheit

  P201：Vor Gebrauch besondere Anweisungen einholen.

  P202：Vor Gebrauch alle Sicherheitshinweise lesen und verstehen.

  P260：Dampf/Aerosol/Nebel nicht einatmen.

  P263：Kontakt während der Schwangerschaft /und der Stillzeit vermeiden.

  P264：Nach Gebrauch gründlich waschen.

  P264：Nach Gebrauch gründlich waschen.

  P270：Bei Gebrauch nicht essen, trinken oder rauchen.

  P281：Vorgeschriebene persönliche Schutzausrüstung verwenden.

  P308+P313：BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

  P314：Bei Unwohlsein ärztlichen Rat einholen / ärztliche Hilfe hinzuziehen.

  P405：Unter Verschluss aufbewahren.

  P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

9-Fluoro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione 17-valerate Chemische Eigenschaften,Einsatz,Produktion Methoden

• Originator

  Valisone,Schering,US,1967

• Verwenden

  Dexamethasone Valerate (Betamethasone Valerate EP Impurity C) is an impurity of Dexamethasone (D298800), which is a glucocorticoid that is used as an anti-inflammatory agent. Dexamethasone regulates T cell survival, growth, and differentiation. Dexamethasone inhibits the induction of nitric oxide synthase.

• Definition

  ChEBI: Dexamethasone valerate is a 21-hydroxy steroid.

• Manufacturing Process

  The valerate is made from betamethasone as a starting material as follows: A suspension of 9α-fluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene- 3,20-dione(betamethasone) (2 grams) in sodium dried benzene (500 ml) was distilled vigorously for a few minutes, toluene-p-sulfonic acid monohydrate (30 mg) and methyl orthovalerate (5 ml) were added and distillation was continued for 10 minutes. The mixture was then boiled under reflux for 1.5 hours after which time unreacted betamethasone alcohol (400 mg) was removed by filtration. The benzene solution was treated with solid sodium .bicarbonate and a few drops of pyridine, filtered and evaporated to dryness at about 50°C. The residue, in ether, was filtered through grade III basic alumina (20grams) to remove traces of unreacted betamethasone alcohol, the ether removed in vacuo and the residue of crude betamethasone 17,21- methyl orthovalerate was treated with acetic acid (20ml) and a few drops of water and left overnight at room temperature.
  The acetic acid solution was poured into water (100 ml) and extracted with chloroform. The chloroform extracts were washed in turn with water, saturated sodium bicarbonate solution and water, dried and evaporated in vacuo. The residual gum was triturated with ether and a white crystalline solid (1.16 grams) isolated by filtration. Recrystallization from ether (containing a small amount of acetone)-petroleum ether gave 9α-fluoro-11β,21-dihydroxy-16β- methyl-17α-valeryloxypregna-1,4-diene-3,20-dione (871 mg) as fine needles.

• Therapeutic Function

  Corticosteroid

9-Fluoro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione 17-valerate Upstream-Materialien And Downstream Produkte

9-Fluor-11β,17,21-trihydroxy-16α-methylpregna-1,4-dien-3,20-dion-17-valerat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(59)Suppliers

33755-46-3, 9-Fluoro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione 17-valerate Verwandte Suche: